Information Provided By:
Fly News Breaks for February 21, 2017
EXAS
Feb 21, 2017 | 14:08 EDT
As previously reported, Benchmark analyst Raymond Myers took over coverage of Exact Sciences and upgraded the stock to Buy, saying he increasingly sees the company as a marketing platform for internally developed, and potentially acquired, diagnostics with Cologuard now covered for the majority of patients. The analyst, who noted that the company plans to present data for its developmental lung cancer blood test in April, set a $27 price target on the shares.
News For EXAS From the Last 2 Days
There are no results for your query EXAS
I agree to the thefly.com's disclaimer & terms of use
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.